Press Releases

Latest Brainlab software for treatment of brain metastases and benign skull base tumors presented by leading clinicians at ISRS

Latest Brainlab software for treatment of brain metastases and benign skull base tumors presented by leading clinicians at ISRS

Yokohama, Japan, June 03, 2015—Experts in stereotactic radiosurgery (SRS) from all over the globe will be presenting Brainlab software innovations at this year’s International Stereotactic Radiosurgery Society Congress in Yokohama. With the theme of this year’s congress “Meet the Experts and Share the Experiences”, Brainlab will provide a platform for these leading experts to discuss various advancements in SRS technology and treatments.


“We are pleased to welcome such accomplished experts at this year’s ISRS in Japan,” commented Thomas Kraft, President RoW and Japan at Brainlab. “Based on the increase of our ExacTrac® Patient Positioning System installed base in Japan—which more than doubled in 2014 and has already achieved two thirds of that number so far in 2015—we consider ISRS in Yokohama the ideal location to showcase our latest developments in indication-specific SRS treatment planning and delivery.”

All expert presentations relate to two new Brainlab software technologies, Automatic Brain Metastases Planning Software, which consistently and rapidly generates radiosurgery plans for efficient treatment of multiple metastases and Adaptive Hybrid Surgery Analysis, which helps balance surgical risk with radiosurgical toxicity when treating benign skull base tumors.“Complex skull base tumors present a treatment challenge because of the need for multi-modality therapy where overly aggressive surgical resection can potentially lead to disabling neurologic morbidity,” commented Dr. Igor Barani of University of California, San Francisco, USA, who will give two presentations for Brainlab at ISRS, “Adaptive Hybrid Surgery Analysis represents a novel approach that attempts to identify a resection extent beyond which additional surgery may not alter tumor control outcomes in the setting of adjuvant radiation therapy or radiosurgery.”

Other renowned speakers include Yoshimasa Mori, MD from Aichi Medical University, Aichi, Japan; Marc Levivier, MD, from Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Guus Beute, MD, St. Elisabeth Hospital Gamma Knife Center, Tilburg, The Netherlands; Roberto Spiegelmann, MD, Chaim Sheba Medical Center, Tel Aviv, Israel and Thierry Gevaert, PhD, Brussels University Hospital, Brussels, Belgium.

About Brainlab

Brainlab develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.
Brainlab technology powers treatments in radiosurgery as well as numerous surgical fields including neurosurgery, orthopedic, ENT, CMF, spine and trauma. Founded in Munich in 1989, Brainlab has over 8,900 systems installed in about 100 countries.

To learn more about Brainlab, visit